Posted: 05/13/2025 07:05 am
DiaMedica Therapeutics Inc. (NASDAQ: DMAC), a clinical-stage biopharmaceutical company focused on developing treatments for conditions such as acute ischemic stroke and preeclampsia, recently released its financial results for the year ending December 31, 2024. This report comes on the heels of ongoing developments and strategic moves within the company, with a focus on compensation trends that provide a lens into its corporate priorities.
A deep dive into the compensation packages over recent years reveals a consistent increase in total executive compensation, which has aligned with the company's evolving strategic goals. For instance, Scott Kellen, Chief Financial Officer and Secretary, received a total compensation of $813,955 in 2024, a notable increase from his 2023 compensation of $632,215. The significant components of his compensation include an option award of $274,521 in 2024, up from $146,790 in 2023, as well as an increase in incentive plan compensation from $116,025 in 2023 to $147,934 in 2024^1^2. This upward trend highlights DiaMedica's focus on rewarding strategic contribution, especially amidst a challenging economic landscape in the pharmaceutical sector.
In comparison, the previous years saw different leaders at the helm, with Kirsten Gruis, M.D., receiving a total compensation of $1,004,691 in 2022, including a substantial option award of $487,789^3. This strategy suggests DiaMedica's reliance on robust compensation as a tool for attracting and retaining top-tier leadership talent crucial for advancing its clinical programs.
Alongside these developments, DiaMedica has also been in the news for its financial performance, as highlighted in recent earnings call transcripts. The company reported its full-year 2024 results on March 17, 2025, noting significant progress in its clinical pipeline^4. The financial and business updates were further discussed in a conference call on March 18, 2025, where key executives, including President and CEO Rick Pauls, participated^5.
On the stock market front, DiaMedica's stock has shown some volatility but maintains a stable presence, closing at $3.825 with a positive change of 4.5082% recently. The stock's current market metrics, such as a market cap of $163,923,053 and an average volume close to 92,013 shares, position it as a consistent player in the NASDAQ index^6. With a 52-week high of $6.8184 and a low of $2.14, the company reflects a responsive market environment to its internal corporate strategies and external market conditions.
As DiaMedica continues its journey in pharmaceutical development, the alignment of compensation with business objectives and the strategic narratives around its financial updates will significantly influence its future trajectory. These moves signal robust corporate governance aligned with shareholder interests and long-term growth strategies.
:
1. “Scott Kellen Total Compensation 2024,” SEC Filing, https://www.sec.gov/Archives/edgar/data/1401040/000143774925009696/0001437749-25-009696-index.htm
2. “Scott Kellen Total Compensation 2023,” SEC Filing, https://www.sec.gov/Archives/edgar/data/1401040/000143774924010985/0001437749-24-010985-index.htm
3. “Kirsten Gruis Total Compensation 2022,” SEC Filing, https://www.sec.gov/Archives/edgar/data/1401040/000143774923009169/0001437749-23-009169-index.htm
4. “DiaMedica Financial Results Announcement,” BusinessWire, https://www.businesswire.com/news/home/20250317880582/en/DiaMedica-Therapeutics-Provides-a-Business-Update-and-Announces-Full-Year-2024-Financial-Results/
5. “DiaMedica Q4 2024 Earnings Call,” Seeking Alpha, https://seekingalpha.com/article/4768449-diamedica-therapeutics-inc-dmac-q4-2024-earnings-call-transcript
6. “Current Price Snapshot of DMAC,” Market Data.
